Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
| dc.contributor.author | van den Bent, M | |
| dc.contributor.author | Baumert, B | |
| dc.contributor.author | Erridge, S | |
| dc.contributor.author | Vogelbaum, M | |
| dc.contributor.author | Nowak, A | |
| dc.contributor.author | Sanson, M | |
| dc.contributor.author | Brandes, A | |
| dc.contributor.author | Clement, P | |
| dc.contributor.author | Baurain, J | |
| dc.contributor.author | Mason, W | |
| dc.contributor.author | Wheeler, H | |
| dc.contributor.author | Chinot, O | |
| dc.contributor.author | Gill, S | |
| dc.contributor.author | Griffin, M | |
| dc.contributor.author | Brachman, D | |
| dc.contributor.author | Taal, W | |
| dc.contributor.author | Rudà, R | |
| dc.contributor.author | Weller, M | |
| dc.contributor.author | McBain, Catherine A | |
| dc.contributor.author | Reijneveld, J | |
| dc.contributor.author | Enting, R | |
| dc.contributor.author | Weber, D | |
| dc.contributor.author | Lesimple, T | |
| dc.contributor.author | Clenton, S | |
| dc.contributor.author | Gijtenbeek, A | |
| dc.contributor.author | Pascoe, S | |
| dc.contributor.author | Herrlinger, U | |
| dc.contributor.author | Hau, P | |
| dc.contributor.author | Dhermain, F | |
| dc.contributor.author | van Heuvel, I | |
| dc.contributor.author | Stupp, R | |
| dc.contributor.author | Aldape, K | |
| dc.contributor.author | Jenkins, R | |
| dc.contributor.author | Dubbink, H | |
| dc.contributor.author | Dinjens, W | |
| dc.contributor.author | Wesseling, P | |
| dc.contributor.author | Nuyens, S | |
| dc.contributor.author | Golfinopoulos, V | |
| dc.contributor.author | Gorlia, T | |
| dc.contributor.author | Wick, W | |
| dc.contributor.author | Kros, J | |
| dc.date.accessioned | 2017-09-08T11:34:31Z | |
| dc.date.available | 2017-09-08T11:34:31Z | |
| dc.date.issued | 2017-08-08 | |
| dc.identifier.citation | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. 2017 Lancet | en |
| dc.identifier.issn | 1474-547X | |
| dc.identifier.pmid | 28801186 | |
| dc.identifier.doi | 10.1016/S0140-6736(17)31442-3 | |
| dc.identifier.uri | http://hdl.handle.net/10541/620551 | |
| dc.description.abstract | The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Lancet (London, England) | en |
| dc.title | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. | en |
| dc.type | Article | en |
| dc.contributor.department | Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands | en |
| dc.identifier.journal | Lancet | en |
| html.description.abstract | The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas. |